Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sun Yat-sen Univ. PARP-1 compound 13f
- Development stage
- Preclinical
- Lead developer
- Sun Yat-sen University
01
Overview
Sun Yat-sen Univ. PARP-1 compound 13f: sourced facts only. name: "Furthermore, 13f exhibited excellent PARP-1 inhibitory effect with IC50 = 0.25 nM." [PMID:36921527]; target: "Furthermore, 13f exhibited excellent PARP-1 inhibitory effect with IC50 = 0.25 nM." [PMID:36921527]; developer: "School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China." [PMID:36921527]; stage: "Among them, compound 13f exhibited the most potent anticancer activity against HCT116 cells and DLD-1 cells with IC50 = 0.30 μM and 2.83 μM, respectively." [PMID:36921527]
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on Sun Yat-sen Univ. PARP-1 compound 13f.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Yat-sen Univ. PARP-1 compound 13f.